The Tell-Tale Heart: The Pharmacist's Cardiovascular Digest

• 17: New Frontiers in Hypertension Care: Insights from the KARDIA-3 and Bax Hypertension Trials

  KARDIA-3 Study KARDIA 3 Study Design KARDIA 2 Study BaxHTN Study Shelby Tungate Lopez, PharmD, CPP, BCACP, MPA is a clinical pharmacist practitioner at the UNC Eshelman School of Pharmacy. He can be reached on Linkedin @ShelbyTungateLopez, and more information can be found about his interests and work at his faculty page.

  --------  

  54:20

  --------

  54:20
• 16: Deconstructing Meta-Analyses From ESC 2025

  Pooled Analysis From VICTOR and VICTORIA Trials β Blocker After Myocardial Infarction Meta Analysis

  --------  

  54:46

  --------

  54:46
• 15: ESC 2025 Highlights: Insights on ALONE-AF and AQUATIC Trials

  Host Craig Beavers sits down with Lorenz van der Linden, a Belgian pharmacist, to dive deep into 2 groundbreaking trials from the European Society of Cardiology (ESC) 2025 Congress. They explore the ALONE-AF trial, which examined anticoagulation strategies for patients with atrial fibrillation after catheter ablation, and the AQUATIC trial, which investigated the role of aspirin in patients on oral anticoagulation. With their expert analysis, Craig and Lawrence break down the clinical implications, methodological nuances, and potential practice-changing insights from these important cardiovascular studies. Show notes: ALONE-AF findings AQUATIC findings

  --------  

  42:16

  --------

  42:16
• 14: Sifting Through Discordant Data From ESC 2025

  Following the European Society of Cardiology Congress 2025, experts sat down again with host Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS (AQ-cards), CACP, to discuss key findings from the meeting. Kaitlin Hile, PharmD, BCCP; Robert Page, PharmD, MSPH, BCPS (AQ-cards), BCGP, FAHA, FHFSA, FCCP, FASHP; and Robert DiDomenico, PharmD, FCCP, FHFSA, FACC, reviewed new data from the meeting and parsed through their lingering questions. Show Notes: Beta-Blockers After Myocardial Infarction Without Reduced Ejection Fraction (REBOOT; NCT03596385) Beta-Blockers After Myocardial Infarction in Patients Without Heart Failure (BETAMI–DANBLOCK; NCT03646357, NCT03778554) Digitoxin in Patients With Heart Failure and Reduced Ejection Fraction (DIGIT-HF) Vericiguat in Patients With Chronic Heart Failure and Reduced Ejection Fraction (VICTOR): A Double-Blind, Placebo-Controlled, Randomized, Phase 3 Trial (NCT05093933)

  --------  

  50:17

  --------

  50:17
• 13: From Guidelines to Action: Pharmacy’s Role in Hypertension Management

  In this episode, host Craig Beavers sits down with Gary Owen, clinical pharmacist and manager of Population Health Pharmacy Services at Vanderbilt University Medical Center, to discuss the newly updated ACC/AHA hypertension guidelines and what they mean for pharmacists. Gary shares how his team supports primary care providers across the state through collaborative practice agreements, innovative telephonic care models, and value-based care initiatives. The conversation explores how pharmacists can play a pivotal role in optimizing medication management, improving patient access, and driving better outcomes in chronic disease care. Read the guidelines here.

  --------  

  40:40

  --------

  40:40

Más podcasts de Ciencias

Podcasts a la moda de Ciencias

Acerca de The Tell-Tale Heart: The Pharmacist's Cardiovascular Digest